Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute lymphoblastic leukaemia Age: Adult |
Dose: Intravenous – 1.4-1.5 mg/m2 Frequency: once weekly Note: Maximum: 2 mg weekly. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of administration. |
|
Indication: Acute lymphoblastic leukaemia Age: Adult Condition: Hepatic impairment with serum bilirubin greater than 3 mg/100ml |
Dose: Intravenous – Reduce dose by 50% Frequency: once weekly Note: Dose adjustment may be needed for hepatic impairment. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of administration. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute lymphoblastic leukaemia Age: Child |
Dose: Intravenous – 1.5-2 mg/m2 Frequency: once weekly Note: Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of administration. |
|
Indication: Acute lymphoblastic leukaemia Age: Child |
Dose: Intravenous – Initiate at 0.05 mg/kg Frequency: once weekly Note: Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of administration. |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment |
Dose: Dose adjustment not necessary Note: Dosage adjustment not necessary in patients with renal impairment. |
Administration
- IV administration only
- Must not be given intrathecally
Side Effect
- Alopecia (20-70%)
- Dose limiting neurotoxicity (eg motor function impairment, gait abnormalities)
- hyperuricaemia
- bronchospasm
- azospermia
- amenorrhoea
- alopoecia
- leucopenia
- urinary dysfunction
- abdominal cramps
- vomiting
- diarrhoea
- severe constipation
- paralytic ileus
- convulsions
- hypertension
- orthostatic hypotension
- ptosis
- hoarseness
- optic neuropathies
- hallucinations
- blindness
- neurological deafness
- difficulty in walking
- syndrome of inappropriate ADH secretion
- Myelosuppression
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Antineoplastic regimens
|
Decreased digoxin (tablets) and verapamil absorption
|
|
Etoposide
|
Increased etoposide serum levels
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Charcot-Marie-Tooth Syndrome
|
Risk of severe neurotoxicity
|
|
Intrathecal Administration
|
Can be fatal
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 2-8° C. Protect from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.